Sign in or create an account to add this stock to your watchlist.
About Maxygen (NASDAQ:MAXY)
Maxygen, Inc. (Maxygen) is a biotechnology company focused on the development of its MAXY-G34 product candidate. MAXY-G34 is a pegylated, granulocyte colony stimulating factor (G-CSF), for the treatment of chemotherapy-induced neutropenia and acute radiation syndrome (ARS). On May 16, 2011, Astellas Pharma Inc. (Astellas) acquired the Company's interests in Perseid Therapeutics LLC, the Company's former subsidiary, which included all of the Company's research and development operations. As a result of the transaction, the Company has reclassified the operating results of Perseid, as well as any related business activities, to discontinued operations. The Company's wholly owned subsidiaries include Maxygen Holdings (U.S.), Inc., Maxygen ApS and Maxygen Holdings, Inc., and its majority owned subsidiary, Maxygen Holdings LLC.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on EquityN/A
Return on AssetsN/A
Maxygen (NASDAQ:MAXY) Frequently Asked Questions
What is Maxygen's stock symbol?
Maxygen trades on the NASDAQ under the ticker symbol "MAXY."
Has Maxygen been receiving favorable news coverage?
Media coverage about MAXY stock has trended somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Maxygen earned a coverage optimism score of 0.10 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 47.11 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
How do I buy shares of Maxygen?
Shares of MAXY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Maxygen?
Maxygen's mailing address is 725 San Aleso Ave Ste 2, SUNNYVALE, CA 94085-1400, United States. The biotechnology company can be reached via phone at +1-650-2412292.
MarketBeat Community Rating for Maxygen (MAXY)MarketBeat's community ratings are surveys of what our community members think about Maxygen and other stocks. Vote "Outperform" if you believe MAXY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MAXY will underperform the S&P 500 over the long term. You may vote once every thirty days.
Maxygen (NASDAQ:MAXY) Analyst Ratings History
(Data available from 5/21/2016 forward)
|Date||Brokerage||Action||Rating||Price Target||Impact on Share Price||Details|
Maxygen (NASDAQ:MAXY) Earnings History and Estimates Chart
Maxygen (NASDAQ MAXY) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Maxygen (NASDAQ:MAXY) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Maxygen (NASDAQ MAXY) Insider Trading and Institutional Ownership History
Maxygen (NASDAQ MAXY) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
Maxygen (NASDAQ MAXY) News Headlines
No headlines for this company have been tracked by MarketBeat.com
Maxygen (NASDAQ:MAXY) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Maxygen (NASDAQ:MAXY) Income Statement, Balance Sheet and Cash Flow Statement
Maxygen (NASDAQ MAXY) Stock Chart for Monday, May, 21, 2018